Casey Ng

A territory-wide, multi-centre, age- and prostate-specific antigen-matched study comparing between chemohormonal therapy and hormonal therapy-alone in Chinese men with metastatic hormone-sensitive prostate cancer

Background There is a lack of real‐world data regarding the treatment outcomes of chemohormonal therapy versus hormonal therapy alone in Chinese men with metastatic hormone‐sensitive prostate cancer. Patients and Methods We conducted a territory‐wide, multicenter, age‐ and prostate‐specific antigen (PSA)‐matched cohort study comparing chemohormonal therapy and hormonal therapy alone in Chinese men with metastatic hormone‐sensitive prostate cancer. Patient and disease characteristics were reviewed. The primary outcome was PSA progression‐free survival. Secondary outcomes included clinical progression‐free survival and castration resistance‐free survival. Kaplan‐Meier and multivariate Cox regression analyses were performed. Results From January 2015 to July 2016, 32 Chinese men with metastatic hormone‐sensitive prostate cancer were treated with chemohormonal therapy, and they were matched to 32 Chinese men who were treated with hormonal therapy alone. Patient and disease characteristics were similar between the 2 groups. The chemohormonal therapy group had a significantly better PSA progression‐free survival (P = .001) and castration resistance‐free survival (P = .002) than the hormonal therapy group. There was no significant difference in the clinical progression‐free survival between the 2 groups. Upon multivariate Cox regression analyses, the use of chemohormonal therapy was significantly associated with a longer time to PSA progression (hazard ratio, 0.31; 95% confidence interval, 0.31‐0.73; P = .008) and a longer time to castration resistance (hazard ratio, 0.38; 95% confidence interval, 0.17‐0.83; P = .015), but was not associated with clinical progression. Conclusions The use of chemohormonal therapy could prevent PSA progression and the development of castration resistance when compared with hormonal therapy alone in Chinese men with metastatic hormone‐sensitive prostatic cancer. Micro‐Abstract We conducted a territory‐wide, multicenter, age‐ and prostate‐specific antigen‐matched cohort study comparing chemohormonal therapy and hormonal therapy alone in Chinese men with metastatic hormone‐sensitive prostate cancer. Our study showed that the use of chemohormonal therapy could prevent prostate‐specific antigen progression and the development of castration resistance when compared with hormonal therapy alone in Chinese men with metastatic hormone‐sensitive prostatic cancer.

PD57-01 HEMATURIA RISK INDEX - RISK OF UROTHELIAL MALIGNANCY IN PATIENTS WITH ASYMPTOMATIC MICROSCOPIC HEMATURIA

CONCLUSIONS: Only a quarter of our respondents utilize FT in their practice with surgeon’s experience being the only independent predictor for utilizing FT. Majority of respondents though consider FT to be beneficial in prostate cancer management and would use it more often if provided more reliable and cost effective options. Over time, experience and accessibility to reliable methods to perform FT may lead to further utilization of this novel treatment strategy.

Characteristics and clinical outcomes of living renal donors in Hong Kong

INTRODUCTION In Asia, few reports are available on the outcomes for living renal donors. We report the short- and long-term clinical outcomes of individuals following living donor nephrectomy in Hong Kong. METHODS We retrospectively reviewed the characteristics and clinical outcomes of all living renal donors who underwent surgery from January 1990 to December 2015 at a teaching hospital in Hong Kong. Information was obtained from hospital records and territory-wide electronic patient records. RESULTS During the study period, 83 individuals underwent donor nephrectomy. The mean (± standard deviation) follow-up time was 12.0 ± 8.3 years, and the mean age at nephrectomy was 37.3 ± 10.0 years. A total of 44 (53.0%), four (4.8%), and 35 (42.2%) donors underwent living donor nephrectomy via an open, hand-port assisted laparoscopic, and laparoscopic approach, respectively. The overall incidence of complications was 36.6%, with most being grade 1 or 2. There were three (9.4%) grade 3a complications; all were related to open donor nephrectomy. The mean glomerular filtration rate was 96.0 ± 17.5 mL/min/1.73 m2 at baseline and significantly lower at 66.8 ± 13.5 mL/min/1.73 m2 at first annual follow-up (P<0.01). The latest mean glomerular filtration rate was 75.6% ± 15.1% of baseline. No donor died or developed renal failure. Of the donors, 14 (18.2%) developed hypertension, two (2.6%) had diabetes mellitus, and three (4.0%) had experienced proteinuria. CONCLUSION The overall perioperative outcomes are good, with very few serious complications. The introduction of a laparoscopic approach has decreased perioperative blood loss and also shortened hospital stay. Long-term kidney function is satisfactory and no patients developed end-stage renal disease. The incidences of new-onset medical diseases and pregnancy-related complications were also low.